Forbes January 13, 2026
Nvidia on Monday announced plans to invest $1 billion over the next five years in a potentially groundbreaking joint laboratory with pharmaceutical giant Eli Lilly, and the goal is enormous — to supercharge the slow, costly process of drug discovery by integrating advanced artificial intelligence directly into laboratory workflows.
The facility will be built in Silicon Valley, placing Lilly’s deep pharmaceutical research expertise right alongside AI innovation. The lab will leverage Nvidia’s BioNeMo platform, a suite of AI models designed to analyze molecular structures and speed the process of identifying promising drug candidates. The collaboration is designed as a two-way knowledge transfer: AI engineers from Nvidia will gain hands-on experience with real-world lab equipment, while Lilly’s scientists will work to...
Today's Sponsors
Today's Sponsor